Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cryopreservation Study Points The Way To Future Skin Indications For Ortec

This article was originally published in The Gray Sheet

Executive Summary

Ortec International will submit results of an equivalence study to FDA demonstrating that its OrCel composite cultured skin (CCS) continues to effectively heal wounds after prolonged cryopreservation.

You may also be interested in...



Ortec OrCel Labeling Should Include Patient Criteria, Steroid Impact - Panel

Ortec International may have to rely on a presentation of pivotal study data in its labeling for OrCel composite cultured skin to make a case for the product's superiority over conventional burn autograft donor site dressings.

Ortec OrCel Labeling Should Include Patient Criteria, Steroid Impact - Panel

Ortec International may have to rely on a presentation of pivotal study data in its labeling for OrCel composite cultured skin to make a case for the product's superiority over conventional burn autograft donor site dressings.

Ortec CCS Venous Leg Ulcer PMA Due 2002; Panel Will Review Burn Indication

Ortec International plans to file a PMA supplement for its composite cultured skin (CCS) for venous skin ulcer treatment by mid-2002, according to company officials.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015176

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel